ImprimisRx (ImprimisRx CA Inc.), Irvine, CA

Is ImprimisRx (ImprimisRx CA Inc.) registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility, with FDA’s note “Out of business”.

Does ImprimisRx (ImprimisRx CA Inc.) hold a California pharmacy license?

No license with this exact name and city was found in the California State Board of Pharmacy file dated Nov 6, 2026. A pharmacy can hold its license under a different legal name, so this is not a finding that it is unlicensed. The file lists current licenses only, not revoked, surrendered or cancelled ones.

Has ImprimisRx (ImprimisRx CA Inc.) had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter (Mar 26, 2019) for ImprimisRx (ImprimisRx CA Inc.). State board actions: no California State Board of Pharmacy action under this exact name and city was found in the board’s posted disciplinary decisions on facility licenses (actions dated Jan 5, 2005 to Oct 28, 2026) on Nov 6, 2026.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
ImprimisRx CA Inc.; ImprimisRx
Location
Irvine, CA
Type as FDA labels it
503A
FDA’s note
Out of business
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
0
Warning letters on FDA’s actions page
1
Latest action on that page
Mar 26, 2019
FDA Data Dashboard inspections
1 inspection: 1 OAI; 3 published Form 483s
Form 483 text on this page
3 Form 483s, 18 observations
State board records
No exact match

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as ImprimisRx CA Inc. (dba ImprimisRx), a 503A facility, with 1 dated action.

Document
Mar 26, 2019Warning letterWarning Letter (03/26/2019)FDA copy (archived)

A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists ImprimisRx CA, Inc., Irvine, CA (FEI number 3003436217), matched to this page by exact name, city and state. It lists 1 inspection: 1 OAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Mar 14, 2016Official Action Indicated (OAI)Drug Quality Assurance (Drugs)3003436217962695

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483s for this site have 18 numbered observations in all, across 3 inspections ending Mar 14, 2016 to Mar 27, 2017. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Mar 27, 2017: 3 observations

Firm on the cover
, 9257 Research Drive
FEI number
3003436217
Establishment type on the cover
Producer of Sterile Drugs Irvine, CA 92618 -4286
FDA district office on the cover
19701 Fairchild Irvine, CA 92612-2445
Matched to this page by
FEI number on the cover; linked from Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.

Observation 1

Aseptic processing areas are deficient regarding air supply that is filtered through high-efficiency particulate air filters under positive pressure.

Specifically,

a) It was observed that during product vial filling of Ascorbic Acid P-F 500mg/ml injection lot

03202017@ 1B in the Clean Room IS0-5 REDACTED (b)(4) zone, a cart was left sitting for 15-20 minutes between plastic curtains resulting in exposure of the IS0-5 zone to IS0-7 area. Large equipment such as REDACTED (b)(4) pump, metal rack, REDACTED (b)(4) in-process glassware and other supplies were set in the LAFW Hood REDACTED (b)(4) during use, blocking the movement of first-air passage. Non-viable particle monitoring is placed in the REDACTED (b) (4)

b)The smoke studies performed on REDACTED (b)(4) showed displaced air currents due to the REDACTED (b)(4) pump. These smoke studies were not performed under normal dynamic conditions with the typical amount of equipment including glassware, racks, or other equipment that block the HEPA air flow. ...

Read the full 483 (PDF on fda.gov)

Observation 2

Complaint records are deficient in that they do not include the findings of the investigation and follow up. S

pecifically,

a) The following investigations were not adequate:

• On 03/10/17 the firm received initial notification via telephone of an adverse event due to the intravenous administration of a Curcumin solution. CLR-GEN-IPG-002 entitled "Product Complaint Handling", Version: Authorized By: 11/29/16, states that <Redacted B4>. This adverse event was not documented on complaint or adverse event forms.

• In 2016 and the first quarter of 2017 there have been 69 Quality Related Events (QRE), including ADEs and product quality complaints, including the ADE above. The QRE investigation and documentation process needs to be fortified to include critical information such as the date, prescription (Rx) number, lot number and other pertinent information, for example: incorrect drug, dosage strength, or dosage form. ADEs require complete investigations and corrective actions.

rREDACTED (b)(6) REDACTED (b)(7)(c) a n d REDACTED (b)(6) REDACTED (b)(7)(c) employee training files do not include training on the most current complaint procedure. b)

Observation 3

The quality control unit lacks authority to fully investigate errors that have occurred.

Specifically,

In 2016 and the first quarter of 2017 there have been 69 Quality Related Events (QRE), including ADEs and product quality complaints. The pharmacists and pharmacy technicians contribute to the production of the firm and are included in the QA/QRE review. However, your firm Jacks a separate Quality Control Unit to implement corrective actions and complete investigations to ensure quality and prevent QREs. For example:

a) T here were approximately three customer complaints in the first quarter of 2017, dated 1 /10/17, 03

/06/17, and 03/15/17, and the corresponding form s, whic h incl uded inve stigations, were not revi ewed by Q ual ity Assu rance (QA), as p er CLR- GEN-IPG-002 whic h stat es that complaint inve stigations REDACTED (b)( 4) and REDACTED (b) (4 )

b) QRE REDACTED (b)(4) reviews conducted by pharmacists and pharmacy technicians highlight the need for improvements for training and quality.

Theresa Ki

Inspection dated Sep 1, 2016 by FDA (dates on the form not read): 7 observations

Firm on the cover
, 9257 Research Dr
FEI number
3003436217
Establishment type on the cover
P Irvine, CA 92618-4286 roducer o f s terile d rugs
FDA district office on the cover
19701 Fairchild Irvine, CA 92612
Matched to this page by
FEI number on the cover; linked from Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.

Observation 1

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

Specifically, A. Active viable air monitoring is not performed in the ISO 5 hood each day during production of injectable drug products,

instead viable air monitoring is currently performed REDACTION (b)(4) according to the firm's procedu re #6.5.0 titled " Environmental monitoring".

B. Environmental monitoring of the ISO 5 hood surfaces is not performed at the end of each day that a batch of sterile product is filled, i nstead surface monitoring is currently performed R EDACTION (b)(4) according to the f irm's procedure #6.5.0 titled "Environmental monitoring".

C. Microbiological monitoring of the filling technician's fingertips is not performed each day that a batch of sterile product i

s filled, instead fingertip monitoring is currently performed R EDACTION (b)(4) according to the firm's procedure #6.5.1 titled "Gloved Fingertip Sampling".

D. The firm's current environmental monitoring program does not include any non-viab le particulate monitoring during filling of injectable drug products.

Observation 2

Clothing of personnel engaged in the processing of drug products is not appropriate for the duties they perform.

Specifically, the coverall and face mask worn in the clean room are not sterile. In addition the firm's procedure #2.5.0, titled "Clean Room Attire and Conduct" allows for the non-sterile gowns to be reused during the course of a day.

Observation 3

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not include adequate validation ofthe sterilization process.

Specifically, the Aseptic Technique Personnel Validation which your firm uses to evaluate individual aseptic technique for sterile compounding operations is deficient in that: A. The firm does not incubate all of the vials which are filled during the validation filling session. Only REDACTION ( b)(4) vials out of REDACTION (b)(4) filled vials are incubated.

B. The validation does not represent the maximum amount of bulk product which can be aseptically filled during a filling

operation. The firm's validation only r equires R EDA CTI ON (b)(4) to be ase ptica lly filled into in dividual vials; however during routine operations a bulk product vo lume as large as REDACTION (b)(4) is aseptically filled into individual vials.

C. The validation only require REDACTION (b )(4) of sterile to be filled into each REDACTION (b)(4) v ial, which does not ensure that all surfaces of the vial come into contact with the growth media.

D. ...

Read the full 483 (PDF on fda.gov)

Observation 4

Each batch of drug product purporting to be sterile is not laboratory tested to determine conformance to such requirements. Specifically,

Specifically, A. Suitability testing for the s terility test method, necessary to demonstrate that the product does not interfere with the test, has not been performed by the contract testing laboratory which conducts the release test. For example:

i. Calcium chloride 1 00mg/ml Preservative Free Injectable was filled on 3/26/2014 and released on 4/9/2014. The f irm does not have sterility test suitability data to support the test results obtained.

ii. Zinc Sulfate Preservative Free Injection (Zinc 1 0mg/ml) I njectable was f illed o n 3 /12/2014 an d released on 3/ 31/2014. The firm does not have sterility test suitability data to support the test results obtained.

iii.

Inositol 50mg/ml Solution Injection was f illed on 3/19/2014 and released on 4/4/2014. The firm does not have ste rility test suitability data to support the test results obtained.

Observation 5

Results of stability testing are not used in determining expiration dates.

Specifically, stability s tudies a re n ot p erformed t o s upport b eyond u se d ates ( BUD) of lyophilized dr ug pr oducts. Fo r ex ample:

a. Human Chorionic Gonadotropin 5000 Units/Hydroxopobalamin 2500 meg lyophilized powder for injection is given a BUD of 180 days.

b. Human Chorionic Gonadotropin 10,000 units/ Hydroxocobalam in 5000 meg lyophilized powder for injection is given a BUD of 180 days.

Observation 6

The written stahility progrAm for dn1g products does not include test interval s based on statistical criteria for each attribute examined to assure valid estimates ofstability.

Specifically,

A. Stability testing performed on injectable drug products does not include sterility at the end of the shelf life, for example:

a. The REDACTION (b)(4) month stability study for Ascorbic Acid Preservative Free Inject ion 500mg/ml only includes potency

b. The REDACTION (b)(4) month stability study for Inositol 50mg/ml Injection (multiple dose vial) only includes potency.

B. The REDACTION (b)(4) month stability study for Inositol 50mg/mllnjection in a 30 ml Multiple Dose Vial (preserved with benzalkonium chloride 5%) does not include data to demonstrate that the preservative is effective at the time of release or that it retains antimicrobial effectiveness over the shelf life of the product.

Observation 7

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.

Specifically, disinfectants and sanitizers used to clean ISO 7 areas of the facility such as the mixing room and the buffer room are not rendered sterile prior to use.

Inspection Feb 23, 2016 to Mar 14, 2016: 8 observations

Firm on the cover
FEI number
3003436217
Establishment type on the cover
Producer of Sterile Drugs
FDA district office on the cover
19701 Fairchild, Irvine, CA 92612,
Matched to this page by
FEI number on the cover; linked from Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.

Observation 1

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not include adequate validation of the sterilization process.

Specifically,

A. Policy and Procedure Number 6.2.0 titled "Aseptic Technique Personnel Validation" is deficient in that it does not require the firm to perform media fill simulation with worst case scenario and does not address conducting media runs for the lyophilization process. For example, A. Policy and Procedure Number 6.2.0 titled "Aseptic Technique Personnel Validation" is deficient in that it does not require the firm to perform media fill simulation with worst case scenario and does not address conducting media runs for the lyophilization process. For example,

a. Ascorbic Acid P-F Non-Com 500mglml injectable lot # : 112420 15@488 was made with batch size of REDACTED B4 yielding REDACTED B4 vials (non-sterile to sterile production). The following table lists the media simulation REDACTED B4 not meeting worst case scenario performed by personnel involved in sterile production. a. ...

Read the full 483 (PDF on fda.gov)

Observation 2

Clothing of personnel engaged in the processing of drug products is not appropriate for the duties they perform.

Specifically, Policy and Procedure Number 2.5.3 titled "Donning Sterile Garments" is deficient in that it does not state that forehead and neck areas should be completely covered. On 02/23/16, we observed REDACTED B4 employees working in the ISO 7 room with REDACTED B4 ISO 5 hoods having partially exposed foreheads REDACTED B7C, B6 technician and REDACTED B7C, B6 technician and partially exposed neck are REDACTED B7C, B6 Technician only) while filling sterile Heparin/Lidocaine 3300 lU/ml /265 mg/ml syringes (lot #02232016@2B) and Methylcobalamin25mg/ml (Lot#12032015@2B) respectively.

j . .

Observation 3

Aseptic processing areas are deficient regarding the system for mon itoring environmental conditions.

Specifically,

A. Policy and Procedure Number 6.5.0 titled "Environmental Monitoripg" is deficient in that

a. The firm does not perform environmental monitoring with active air sampling continuously during production ofsterile drug products.

B. Policy and Procedure Number 6.5 .1 titled "Gloved Fingertip Sampling" is deficient in that

tia l qualification of oper at ors working on sterile drug products with no grown result a s shown in the tab le below. This procedure doe s not requir e the firm to roll their fingers from side to side.

a.

ire ope rators to roll their fing ertip s from side to sid e. This pract ice was observed on 03/02/16, durin g environm ental monitoring REDAC

Se ction 1 states “REDACTED B4” and doe s not requ

TED B4. b. "Daily Environmental Monitoring and Gloved Fingertip Sampling Pro gram Log” states to REDACTED B4. On 03 /02/16, we observed personnel sampling was performed on fingertips REDACTED B4. C. The firm follows Policy and Proced ure Number 6.5.2 titled “Glove/Sterile Gown Initial Qualification” to perform ini

Initial qualific ation table

Observation 4

The responsibilities and procedures applicable to the quality control unit are pot in writing and fully followed.

Specifically,

A. SOP number 6.14.0 Titled "Particulate Testing for Sterile Drug Preparations" section IV.6 states that the inspector is to REDACTED B4. However, during the walkthrough on 2/23/2016, we observed the inspector (Pharmacist) only visually inspecting Ascorbic Acid in amber vials (Lot# 022220 16@IB) REDACTED B4. A. SOP numb er 6.14 .0 Titled "Particulate Testing for Sterile Drug Preparations" section IV.6 states that the inspector is to REDACTED B4. However, during the walkthrough on 2/23/2016, we observed the inspector (Pharmacist) only visually inspecting Ascorbic Acid in amber vials (Lot# 022220 16@IB) REDACTED B4. A. SOP number 6.14.0 Titled "Particulate Testing for Sterile Drug Preparations" section IV.6 states that the inspector is to REDACTED B4. However, during the walkthrough on 2/23/2016, we observed the inspector (Pharmacist) only visually inspecting Ascorbic Acid in amber vials (Lot# 022220 16@IB) REDACTED B4

B. ...

Read the full 483 (PDF on fda.gov)

Observation 5

Aseptic processing areas are deficient regarding the system for cleaning and ~ disinfecting the room and equipment to produce aseptic conditions.

I

Specifically,

A. Policy and Procedure Number 4.1.0 titled "Clean Room, Cleaning, and Maintenance of' is deficient in that

b. There is no scientific rationale for the use of sporicidal cleaning agent, REDACTED B4 for REDACTED B4. , 11>> <4> 1 {b)(4 ) }Kb) (4_[ ) -

a. Section B.3 under Cleaning Schedule states "Use REDACTED B4 wipes to clean counters, work surfaces, s cales and equipm ent." Per PIC REDACTED B4 used is non-sterile. :

I

B. Policy and Procedure Number 3.9.0 titled "Lyophilizer Standard Operating Procedure" is deficient in that it does not state

a. whether REDACTED B4 and REDACTED B4 are sterile -in actual practice, the firm used non-sterile REDACTED B4 per the Director of Corporate Development a. whether REDACTED B4 and REDACTED B4 are sterile -in actual practice, the firm used non-sterile REDACTED B4 per the Director of Corporate Development

b. the lyophilizer cleaning log only documents the use of the REDACTED B4 and no REDACTED B4 1

I!

c. ...

Read the full 483 (PDF on fda.gov)

Observation 6

There was a failure to handle and store drug product co~tainers and closures at all times in a manner to prevent contamination.

Specifically,

Policies and Procedures 3.3.1 titled "Vials, REDACTED B4 3.3.2 titled "Glassware for Sterile Compounding REDACTED B4 and 3.3.3 titled REDACTED B4 Stoppers -- REDACTED B4, are deficient in that

J and 3.3.3 titled Pol icies and Procedures 3.3.1 titled "Vials, REDACTED B4 3.3.2 titled "Glassware for Sterile Compounding REDACTED B4 and 3.3.3 titled REDACTED B4 Stoppers -- REDACTED B4, are deficient in that r ---, Policies and Procedures 3.3.1 titled "Vials, REDACTED B4 3.3.2 titled "Glassware for Sterile Compounding REDACTED B4 and 3.3.3 titled REDACTED B4 Stoppers -- REDACTED B4, are deficient in that

I • A. The sterilized vials and stoppers are stored in REDACTED B4 production area for future use as needed without any expiration or end of use date. On 02/23/16, we observed several REDACTED B4 and stopper bags labeled "sterilized" were stored on shelves situated IN REDACTED B4 production area. A. The sterilized via ls and stoppers are stored in REDACTED B4 production area for future use as needed without any expiration or end of use date. ...

Read the full 483 (PDF on fda.gov)

Observation 7

Buildings used in the manufacture, processing, packing or holding of drug products are not maintained in a clean and sanitary condition.

Specifically,

A. The firm has no written procedure to describe the number of items allowed to be placed in ISO 7 filling room. On 02/23/16, we observed this ISO 7 filling room to have REDACTED B4 four carts full of bags, containers on the shelf, and equipment while REDACTED B4 technicians were working.

B. On 02124/16, we observed the double-doors in the back of the facility have gaps at both the bottom (approximately 1/2 inch) and top (approximately 1116 inch) of]the door when they are closed. One of the doors was not tightly shut and the rolling door was also not shut. The double door is located between the non-classified production area and an exterior metal roll up door.

C. On 03102/16, we observed a s ingle door iii the back of the facility had been kept open using a door stopper.

D. ...

Read the full 483 (PDF on fda.gov)

Observation 8

Routine calibration of equipment is not performed according to a written program designed to assure proper performance.

Specifically, the pH meter used to measure the product pH has been calibrated REDACTED B4 pH levels, i.e REDACTED B4. The following products, however, were tested outside the calibrated range:

A. Heparin/Lidocaine, 1/11/16, lot no. 01112016@558, pH REDACTED B4; B. Poly-MY A solutio~ l/8/16, lot no. 01082016@18, pH REDACTED B4; c. Folic Acid solution, 9/17/15, lot no. 09172015@27B, pH REDACTED B4.

State board of pharmacy records

No license with this exact name and city was found in the California State Board of Pharmacy file dated Nov 6, 2026. A pharmacy can hold its license under a different legal name, so this is not a finding that it is unlicensed. The file lists current licenses only, not revoked, surrendered or cancelled ones. Board file.

What this covers: Facility license decisions from the board’s quarterly Disciplinary Actions pages (87 of 88 quarters had a facility section). These are final decisions; accusations filed and immediate protection orders are not included. Actions in the data are dated Jan 5, 2005 to Oct 28, 2026.

Same name at other locations

FDA lists these records under the same name at another location. A shared name does not establish that they are the same firm.

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.